Overview

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Status:
Active, not recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborator:

Canadian Cancer Trials Group

Treatments:

6-Mercaptopurine
Antibodies
Antibodies, Bispecific
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Asparaginase
BB 1101
Blinatumomab
Cortisone
Cortisone acetate
Cyclophosphamide
Cytarabine
Daunorubicin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Etoposide phosphate
Immunoglobulins
Mercaptopurine
Methotrexate
Muromonab-CD3
Pegaspargase
Podophyllotoxin
Prednisone
Rituximab
Vincristine